Victory Capital Management Inc. lifted its holdings in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 101.4% during the 1st quarter, Holdings Channel reports. The firm owned 29,515 shares of the company’s stock after buying an additional 14,859 shares during the period. Victory Capital Management Inc.’s holdings in Medpace were worth $2,166,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Sandy Spring Bank acquired a new stake in shares of Medpace during the first quarter worth about $65,000. Exchange Traded Concepts LLC acquired a new stake in Medpace in the fourth quarter valued at approximately $80,000. Allred Capital Management LLC acquired a new stake in Medpace in the first quarter valued at approximately $87,000. Marshall Wace LLP acquired a new stake in Medpace in the first quarter valued at approximately $99,000. Finally, Nisa Investment Advisors LLC raised its holdings in Medpace by 12.1% in the first quarter. Nisa Investment Advisors LLC now owns 2,185 shares of the company’s stock valued at $160,000 after acquiring an additional 235 shares in the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.

MEDP stock opened at $90.08 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 0.07. Medpace Holdings Inc has a twelve month low of $53.10 and a twelve month high of $109.09. The company’s 50 day moving average is $81.11 and its two-hundred day moving average is $82.74. The stock has a market cap of $3.06 billion, a P/E ratio of 31.06 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.76 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.01). Medpace had a return on equity of 16.96% and a net margin of 12.37%. The company had revenue of $230.88 million for the quarter, compared to analyst estimates of $226.23 million. During the same period in the previous year, the business posted $0.64 EPS. The firm’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, equities research analysts predict that Medpace Holdings Inc will post 2.39 earnings per share for the current year.

Several analysts recently weighed in on the stock. Credit Suisse Group reduced their target price on shares of Medpace from $105.00 to $92.00 and set an “outperform” rating on the stock in a report on Wednesday, April 29th. BidaskClub cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, March 13th. CSFB raised their target price on shares of Medpace from $91.00 to $99.00 and gave the company an “outperform” rating in a report on Tuesday, February 25th. SunTrust Banks raised shares of Medpace from a “sell” rating to a “hold” rating and raised their target price for the company from $54.00 to $85.00 in a report on Thursday, April 30th. Finally, Zacks Investment Research raised shares of Medpace from a “sell” rating to a “hold” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $90.29.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: QQQ ETF

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.